Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-4047 (Pomalidomide) + Dexamethasone in Relapsed/Refractory Multiple Myeloma or Amyloidosis
NCT00558896Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2007
- Primary completion
- Sep 2012
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide in multiple myeloma (MM) and light-chain amyloidosis (7 arms), sponsored by Mayo Clinic. Primary endpoint: Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) up to 3 years. Started Nov 2007; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT00558896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558896.